Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 45 of 157 results for pembrolizumab

  1. Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)

    NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    24 April 2024

    Sections for TA966

  2. Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

    NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the

    Technology appraisal guidance
    Published
    20 March 2019

    Sections for TA570

  3. Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332

    In development [GID-TA11233] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma ID4044

    In development [GID-TA10930] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)

    Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    2 June 2021
    View recommendations

    Sections for TA705

  6. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

    Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    8 February 2023
    View recommendations

    Sections for TA865

  7. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Awaiting development [GID-TA11093] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    Awaiting development [GID-TA10747] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    In development [GID-TA11005] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

    Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 May 2018
    View recommendations

    Sections for TA520

  11. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.

    Technology appraisal guidance
    Published
    8 September 2021
    View recommendations

    Sections for TA724

  13. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    27 July 2016
    View recommendations

    Sections for TA400

  14. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA950

  15. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    10 April 2024
    View recommendations

    Sections for TA964